Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (41-50 of 910) with videos related to

Pageof 91
Sort By:
JAMA Internal Medicine|October 18, 2016
More Evidence That Caffeine Consumption Appears to Be Safe in Patients With Heart FailureJacob P Kelly, Christopher B Granger
Nature Reviews. Cardiology|September 30, 2016
Enhancing the value of clinical trials: the role of data sharingChristopher B Granger, E Magnus Ohman
JACC. Cardiovascular Interventions|March 11, 2017
Out-of-Hospital Cardiac Arrest: To CT or Not to CT?Timothy D Henry, Christopher B Granger
Circulation|August 17, 2011
The need for regional integrated care for ST-segment elevation myocardial infarctionJohn P Vavalle, Christopher B Granger
European Heart Journal|June 7, 2019
Continuous anticoagulation with catheter ablation: answers and questionsSean D Pokorney, Christopher B Granger
Annals of Internal Medicine|March 21, 2017
Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of ageNeha J Pagidipati, Christopher B Granger
American Heart Journal|August 23, 2006
Reflections on early stopping of a clinical trialPaul W Armstrong, Christopher B Granger
JAMA|May 3, 2007
Pexelizumab and the APEX AMI trialPaul W Armstrong, Christopher B Granger
European Heart Journal|January 23, 2010
Clinical trials and registries in cardiovascular disease: competitive or complementary?Christopher B Granger, Bernhard J Gersh
Annals of Internal Medicine|January 21, 2020
In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABGAnthony P Carnicelli, Christopher B Granger
Pageof 91

Showing results (41-50 of 910) with videos related to

Sort By:
Pageof 91
JAMA Internal Medicine|October 18, 2016
More Evidence That Caffeine Consumption Appears to Be Safe in Patients With Heart FailureJacob P Kelly, Christopher B Granger
Nature Reviews. Cardiology|September 30, 2016
Enhancing the value of clinical trials: the role of data sharingChristopher B Granger, E Magnus Ohman
JACC. Cardiovascular Interventions|March 11, 2017
Out-of-Hospital Cardiac Arrest: To CT or Not to CT?Timothy D Henry, Christopher B Granger
Circulation|August 17, 2011
The need for regional integrated care for ST-segment elevation myocardial infarctionJohn P Vavalle, Christopher B Granger
European Heart Journal|June 7, 2019
Continuous anticoagulation with catheter ablation: answers and questionsSean D Pokorney, Christopher B Granger
Annals of Internal Medicine|March 21, 2017
Guideline: The USPSTF recommends low- to moderate-dose statins to prevent CVD in selected adults 40 to 75 years of ageNeha J Pagidipati, Christopher B Granger
American Heart Journal|August 23, 2006
Reflections on early stopping of a clinical trialPaul W Armstrong, Christopher B Granger
JAMA|May 3, 2007
Pexelizumab and the APEX AMI trialPaul W Armstrong, Christopher B Granger
European Heart Journal|January 23, 2010
Clinical trials and registries in cardiovascular disease: competitive or complementary?Christopher B Granger, Bernhard J Gersh
Annals of Internal Medicine|January 21, 2020
In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABGAnthony P Carnicelli, Christopher B Granger
Pageof 91